[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolomics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolomics":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,50,82,115,145,167,191,222,244,277,312,350,379,406,438,463,483,506],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100631210","phase-2-virtual-menstrual-pain-approaches-in-females-100631210",false,"NCT07497711","Virtual Menstrual Pain Approaches in Females","Virtual Auricular Acupressure and Baduanjin Qigong Exercise for Preventing Menstrual Pain in Females: A Randomized Clinical Trial","AABQ","Inclusion Criteria:\n\n* 16 - 35 years of age\n* Regular menstrual cycles (28 days ± 7 days) in 3 months prior to enrollment\n* Two or more episodes of menstrual cramps in the past 2 months, scored at least 4 points on the worst pain item of the Brief Pain Inventory (BPI)\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Ability to download, install, and navigate the study-specific digital content and use its core functions for training, self-guided intervention administration, and data entry\n* Ability to understand the nature of the study and willingness to give informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled neurological diseases, immunodeficiency, bleeding disorders, and allergies\n* The presence of another Axis I disorder not in remission\n* Lactating or pregnant, or those planning to become pregnant in the coming half year\n* Undergoing other trials for pain management during the study period\n* Plan to initiate other pain therapies for menstrual pain management in the proceeding 3 months","FEMALE","16 Years","35 Years",{"count":21,"type":22},145,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","This research study is testing two self-care approaches that may help prevent or reduce period pain in young females with recurrent painful menstrual cramps. Participants will be placed by chance into 1 of 3 groups: auricular acupressure, Baduanjin qigong, or a self-care education comparison group. The auricular acupressure and Baduanjin groups will receive online training and then practice the treatment on their own for 12 weeks. The main question is whether these two approaches can reduce the severity of menstrual pain. The study will also look at whether they can improve other symptoms that often happen with period pain, such as tiredness, poor sleep, anxiety, low mood, trouble concentrating, and reduced physical function. Researchers will also study stool and blood-related biological markers to better understand whether changes in gut bacteria and body metabolism may be linked to symptom improvement. A total of 145 participants will take part in the study at NTU, and any side effects or other safety concerns will be checked every week.",[29,30,31,32,33,34,35,36],"Pain (Visceral, Somatic, or Neuropathic)","Women of Reproductive Age","Mental Disorder","Digital Health","Acupressure","Traditional Exercise","Host-Gut Microbiota Interaction","Metabolomics","RECRUITING","2026-06-18",{"date":40,"type":41},"2026-06-23","ACTUAL",{"date":43,"type":41},"2026-04-15",{"date":45,"type":22},"2029-03-20",{"name":47,"class":48},"Nanyang Technological University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":49},"100639378","influence-of-the-gut-microbiome-on-blueberry-polyphenol-metabolites-100639378","NCT07607158","Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites","BlueBIOME","Inclusion Criteria:\n\n* Healthy adults ≥18 years of age\n* Able and willing to provide informed consent\n* Willing and able to adhere to all study procedures and visit requirements\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Pregnant or breastfeeding\n* Presence of chronic diseases, including but not limited to cardiovascular disease, diabetes, cancer, kidney, liver, gastrointestinal, or pancreatic disease\n* Use of medications for chronic diseases that may interfere with study outcomes\n* Any condition known to negatively impact nutrient absorption (e.g., inflammatory bowel disease, celiac disease, gastroparesis)\n* Anemia (hemoglobin \\\u003C13.5 g\u002FdL in men or \\\u003C12.0 g\u002FdL in women)\n* Body mass index (BMI) ≤18.5 kg\u002Fm²\n* Use of antibiotics within the past 2 months\n* Recent blood draw within 1 week prior to study participation\n* Currently participating in another research study involving a diet or exercise intervention\n* Known allergy or contraindication to blueberry products or study procedures\n* Unwilling or unable to comply with study requirements",true,"ALL","18 Years",{"count":61,"type":22},125,[63],"NA","The objective of this study is to determine whether inter-individual differences in the gut microbiome influence exposure to blueberry polyphenol metabolites. We will use pharmacokinetics of blueberry polyphenols after an acute blueberry exposure to group individuals into \"metabotypes\", groups of individuals based on similarity in their metabolite profiles. We will then use multi-omic approaches to determine whether the gut microbiome predicts an individual's metabotype.",[66,36],"Microbiome Analysis",[68,69,70,71,72],"Microbiome","Polyphenols","Metabotype","Pharmacokinetics","Metabolites","2026-05-19",{"date":75,"type":41},"2026-05-26",{"date":77,"type":41},"2026-01-27",{"date":79,"type":22},"2028-01-01",{"name":81,"class":48},"Colorado State University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":101,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100347976","metabolomics-study-on-postoperative-intensive-care-acquired-muscle-weakness-100347976","NCT03810768","Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness","Metabolomics Pilot Study on Postoperative Intensive Care Acquired Muscle Weakness (MIRACLE-I Study)","MIRACLE I","Inclusion Criteria:\n\n* invasive mechanically ventilated critically ill patient with expected intensive care unit stay \\> 3 days\n* postoperative patient\n* ≥ 18 years old\n* American Society of Anesthesiology (ASA) classification ≥ III\n\nExclusion Criteria:\n\n* moribund patient\n* non-curative care (comfort care)",{"count":91,"type":22},20,"OBSERVATIONAL","In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.\n\nAim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.",[36,95,96,97,98,99,100],"Critical Care","Critical Illness","Critical Illness Myopathy","Critical Illness Polyneuropathy","Intensive Care (ICU) Myopathy","Muscle Weakness",[102,103,104],"pilot trial","muscle biopsy","blood metabolome","2026-02-28",{"date":107,"type":41},"2026-03-03",{"date":109,"type":41},"2022-09-02",{"date":111,"type":22},"2026-12-31",{"name":113,"class":48},"Technical University of Munich",3,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":57,"sex":58,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":49},"100621301","scalp-hair-metabolomics-in-severe-obesity-100621301","NCT07368842","Scalp Hair Metabolomics in Severe Obesity","Scalp Hair Metabolomics as a Novel Biomarker of Poor Metabolic Health in Individuals With Severe Obesity","Inclusion Criteria:\n\nAll subjects:\n\n1. Age 21-70 years\n2. Ability to provide informed consent\n\nHealthy weight controls:\n\n1. BMI of 18.5-24.9 kg\u002Fm2\n2. No chronic disease\n3. No long-term medications\n\nSevere obesity:\n\n1. BMI of \\> 32.5 kg\u002Fm2\n2. Scheduled to undergo bariatric surgery\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Any factors likely to limit adherence to study protocol\n3. Any history of autoimmune or scarring alopecia (eg. alopecia areata, discoid lupus, lichen planopilaris)","21 Years","70 Years",{"count":125,"type":22},60,"The purpose of this research study is to investigate how body weight and weight-loss surgery affect the natural chemicals found in scalp hair over time. We will also find out how common and severe hair thinning\u002Fhair loss and muscle loss are in the first 6 months after bariatric surgery.",[128,129,36,130],"Obesity & Overweight","Hair Loss","Bariatric Surgery",[132,133,134,135],"obesity","hair loss","metabolomics","bariatric surgery","2026-02-11",{"date":138,"type":41},"2026-02-13",{"date":140,"type":41},"2026-02-07",{"date":142,"type":22},"2028-02",{"name":144,"class":48},"Singapore General Hospital",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":57,"sex":58,"minAge":4,"maxAge":4,"enrollmentInfo":152,"targetDuration":154,"studyType":92,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":49},"100624456","an-integrated-multi-omics-study-on-the-molecular-mechanisms-of-ureteral-stricture-100624456","NCT07409870","An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture","US-MOP","Inclusion Criteria (Ureteral Stricture Group):\n\nAge between 18 and 75 years, regardless of gender. Diagnosis of ureteral stricture confirmed by clinical symptoms and imaging (e.g., CT, IVP, or retrograde pyelography) or ureteroscopy.\n\nThe patient is scheduled for or undergoing standard clinical evaluation\u002Ftreatment for ureteral stricture.\n\nWillingness to provide stool, urine, and blood samples. Informed consent signed by the participant or their legal representative.\n\nInclusion Criteria (Healthy Control Group):\n\nAge- and sex-matched volunteers (18-75 years). No history of ureteral stricture, urinary tract obstruction, or significant renal disease.\n\nPhysical examination and laboratory tests (renal function, routine urine analysis) are within normal limits.\n\nExclusion Criteria (Applicable to Both Groups):\n\nUse of antibiotics, probiotics, prebiotics, or antifungal medications within the 4 weeks prior to sample collection.\n\nHistory of chronic gastrointestinal diseases (e.g., Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), or chronic diarrhea).\n\nKnown malignant tumors of the urinary tract or other systemic malignancies. History of major abdominal or urinary tract surgery within the last 3 months (excluding the current planned procedure for patients).\n\nPresence of severe systemic diseases, including uncontrolled diabetes, severe hepatic dysfunction, or end-stage heart failure.\n\nPregnancy or breastfeeding. Any other condition that, in the opinion of the investigator, may interfere with the microbiome or metabolomic analysis.",{"count":153,"type":22},120,"3 Months","The goal of this observational study is to investigate the systemic pathogenesis and identify potential diagnostic biomarkers in patients with ureteral stricture and healthy volunteers. The main questions it aims to answer are:\n\nWhat are the systemic differences in the gut microbiome, urine microbiome, and metabolomic profiles (fecal, urinary, and serum) between patients with ureteral stricture and healthy controls? What are the correlations between these microbial\u002Fmetabolic alterations and clinical phenotypes, such as stricture severity, inflammatory levels, and renal function? Researchers will compare the biological panoramic profiles of patients with ureteral stricture to those of healthy controls to see if specific \"microbiome-metabolite-disease\" regulatory networks drive the development of the condition.\n\nParticipants will:\n\nProvide stool samples for gut microbiome (16S\u002FMetagenomics) and metabolomic analysis.\n\nProvide urine samples for urine microbiome and metabolomic analysis. Provide blood (serum) samples for systemic metabolomic profiling. Undergo clinical assessments, including medical history collection, imaging (e.g., CT\u002FIVP), and laboratory tests (e.g., renal function, inflammatory markers) to evaluate disease severity.",[157,158,68,36],"Ureteral Stricture","Ureteral Obstruction","NOT_YET_RECRUITING",{"date":138,"type":41},{"date":162,"type":22},"2026-02-01",{"date":164,"type":22},"2026-07-31",{"name":166,"class":48},"First Affiliated Hospital of Chongqing Medical University",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":49},"100624593","confirmation-of-the-link-between-endocrine-disruptors-exposure-and-breast-cancer-and-identification-of-biological-response-biomarkers-100624593","NCT07411651","Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Response Biomarkers","EXPOSAL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Female sex\n* Patient with scheduled surgical procedure for removal of a breast lesion\n* Patient who was informed by the surgeon at the preoperative consultation and having signed the consent form\n* Free subject, without guardianship, curatorship or subordination\n* Patients benefiting from a social security scheme or benefiting from such a scheme through a third party\n\nExclusion Criteria:\n\n* Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by judicial or administrative decision, people staying in a health or social establishment, adults under legal protection and patients in emergency situations\n* Pregnant or breast-feeding women.",{"count":175,"type":22},42,[63],"A wide variety of chemicals are constantly being introduced in our environment. The toxicological consequences related to the exposure to these compounds and their impact on public health ar of growing concern. It is now accepted that the occurrence of some non-communicable chronic diseases (diabetes, cancer, cardiovascular diseases…) is the result of complex interactions between environmental factors (chemical, physical and biological) and genetic factors. These non-communicable diseases have significantly increased in recent decades et have become the world's leading cause of deaths. Among these environmental factors, and in particular chemicals, the class of endocrine disruptors (EDs) is of particular concern. EDs are found ubiquitously in our environment. They are found in the natural environment (water, air, soil, etc.) as well as in everyday objects and our food. As a result, the general population is widely exposed to these EDs, which can be measured in a variety of biological media. The collection of biological matrices is essential for studying the exposure of populations to EDs. The choice of biological matrices depends on the physicochemical characteristics of the EDs studied and the type of exposure being assessed. Internal exposure to EDs is most often assessed through blood or urine concentrations in spot samples. Measuring urinary EDs concentrations remains a reference method for biomonitoring bisphenols and parabens. In order to assess long-term exposure to EDs, it was proposed to determine EDs concentrations in hair. In addition to these biological matrices for assessing general short-term and long-term exposure, the use of breast adipose tissue will enable in situ assessment of EDs exposure in the patients included. Moreover, adipose tissue represents an interesting biological matrix for determining exposure to pollutants with short half-lives, such as bisphenols and parabens, particularly when the latter have lipophilic characteristics. In addition, the use of this matrix will enable a non-targeted metabolomics approach to identify possible markers of biological response to EDs exposure, and to determine links between this exposure and carcinogenesis processes.",[179,180,36,181],"Breast Cancer","Endocrine Disruptors","Breast Lesions","2026-02-06",{"date":184,"type":41},"2026-02-17",{"date":186,"type":22},"2026-06-01",{"date":188,"type":22},"2027-02-01",{"name":190,"class":48},"Poitiers University Hospital",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":207,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":49},"100623151","food-intake-related-brain-and-metabolic-responses-in-obesity-100623151","NCT07392905","Food Intake-Related Brain and Metabolic Responses in Obesity","Association Between Food Intake-Related Brain Functional Patterns and Metabolic Profiles in Patients With Obesity: A Randomized Crossover Trial","Inclusion Criteria:\n\nObese participants:\n\n1. BMI ≥ 28 kg\u002Fm²;\n2. Age 18-40 years;\n3. Any gender;\n4. Right-handed.\n\nHealthy control participants:\n\n1. BMI 18.5-23.9 kg\u002Fm²;\n2. Age 18-40 years;\n3. Any gender;\n4. Right-handed.\n\nExclusion Criteria:\n\n1. Diabetes mellitus;\n2. Contraindications or allergies to any ingredient in the standardized meal or macronutrient challenges used in this study;\n3. Central nervous system disorders (e.g., traumatic brain injury, acute cerebral infarction, epilepsy) or psychiatric disorders (e.g., depression, schizophrenia); use of medications acting on the central nervous system within the past 3 months or long-term use;\n4. Severe impairment of liver, kidney, heart, or gastrointestinal function, including alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) levels \\>2 times the upper limit of normal; estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m² calculated by the CKD-EPI equation; history of unstable angina or myocardial infarction within the past 3 months, or heart failure classified as New York Heart Association (NYHA) class II or higher; history of gastrointestinal stoma, bowel resection, intestinal obstruction, or peptic ulcer disease;\n5. Contraindications to MRI, such as implanted metallic devices or claustrophobia;\n6. Pregnancy or lactation;\n7. Participation in another clinical trial currently or within the past 3 months; use of nutritional supplements within the past 3 months or long-term use;\n8. History of prior metabolic\u002Fbariatric surgery;\n9. Use of antibiotics or probiotics within the past 1 month;\n10. Use of medications affecting metabolism or causing weight loss within the past 1 month; body weight fluctuation exceeding 3 kg during the month prior to screening;\n11. Unusual dietary habits; daily alcohol intake \\>40 grams, smoking \\>10 cigarettes per day, or coffee consumption ≥2 cups per day.","40 Years",{"count":125,"type":22},[63],"This study is a prospective, single-center, randomized, controlled, crossover intervention trial. A total of 60 participants, including 30 patients with obesity and 30 healthy controls, will be enrolled. Each participant will receive an isocaloric liquid meal challenge (glucose, fat, or protein) on three separate experimental days, with a washout period of at least 7 days between visits to eliminate carryover effects from the previous intervention. The primary objective is to investigate the association between brain functional patterns and plasma metabolic profiles following the ingestion of different macronutrients in patients with obesity, aiming to uncover potential neuro-metabolic imbalance features.",[203,204,36,205,206],"Obesity","Brain Function","Feeding Behavior","Macronutrients",[132,208,209,210,211,212,213],"macronutrient","fMRI","Cross-over trial","Plasma metabolome","Satiety","Nutrient challenge","2026-01-31",{"date":182,"type":41},{"date":217,"type":41},"2025-12-21",{"date":219,"type":22},"2027-09-01",{"name":221,"class":48},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":57,"sex":58,"minAge":4,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100622236","multi-omics-integrative-analysis-of-serum-and-sputum-to-uncover-key-determinants-of-prognosis-in-patients-with-ards-100622236","NCT07380997","Multi-Omics Integrative Analysis of Serum and Sputum to Uncover Key Determinants of Prognosis in Patients With ARDS","Inclusion Criteria:\n\n* Written and dated informed consent provided.\n* Age ≥18 years.\n* ARDS diagnosed according to the 2012 Berlin definition.\n* Clinically stable\n* eligible for enrollment after 12-24 hours of stability.\n* Baseline oxygenation index (PaO2\u002FFiO2 ≤300 mmHg)\n* No history of major chronic lung disease and no history of immunosuppression.\n* Able to comply with study procedures, including collection of blood\u002Fplasma and sputum samples and clinical data.\n\nExclusion Criteria:\n\n* Severe autoimmune disease or active systemic inflammatory disease.\n* Severe hepatic dysfunction or renal failure requiring dialysis.\n* Invasive mechanical ventilation for \\>36 hours prior to enrollment, or death prior to enrollment.\n* Expected death within 24 hours of admission or inability to complete study-related assessments due to imminent death.\n* Presence of a cardiac pacemaker or other implanted electronic device that may affect respiratory function assessment.\n* Pregnant or breastfeeding women.\n* Severe allergy to materials required for sample collection or other relevant contraindications.\n* Severe psychiatric illness or inability to cooperate with study procedures.\n* Prior participation in other interventional clinical trials that could affect interpretation of study results.\n* Refusal of consent or withdrawal of informed consent.",{"count":229,"type":22},411,"This study is a prospective observational investigation designed to systematically characterize key microbial signatures, metabolite profiles, and gene-expression features in serum and sputum from patients with acute respiratory distress syndrome (ARDS), and to evaluate their associations with response to invasive mechanical ventilation and clinical outcomes. A total of 411 adult ARDS patients meeting the Berlin definition and receiving invasive mechanical ventilation will be enrolled; individuals with significant pre-existing pulmonary disease or a history of immunosuppression will be excluded. Blood and sputum specimens will undergo high-throughput sequencing and metabolomics, including 16S rRNA-based microbiome profiling, whole-transcriptome RNA sequencing, and targeted\u002Funtargeted metabolite quantification by LC-MS\u002FMS. Ventilator-related parameters (e.g., tidal volume, positive end-expiratory pressure \\[PEEP\\], and respiratory system compliance) and clinical endpoints (e.g., 28-day mortality) will be integrated to establish a comprehensive multi-omics analytical framework.\n\nData preprocessing will include batch-effect correction, normalization, and multiple-testing adjustment with false discovery rate control (FDR \\\u003C 0.05). Differential microbes, metabolites, and transcripts will be functionally interpreted using KEGG pathway and Gene Ontology (GO) enrichment analyses. Spearman correlation analyses will be performed to examine associations between omics features and ventilator parameters. Key features will be selected using LASSO regression, followed by development of random forest and support vector machine (SVM) models to predict mechanical ventilation response and the risk of ventilator-induced lung injury (VILI). Model performance will be assessed using ROC curves, area under the curve (AUC), calibration plots, and decision curve analysis.\n\nBy integrating serum and sputum multi-omics data, this study aims to identify molecular biomarkers that influence the effectiveness of mechanical ventilation and prognosis in ARDS, thereby providing evidence to support precision ventilatory strategies and individualized clinical management to improve patient outcomes. The findings are expected to deepen mechanistic understanding of ARDS pathobiology and lay a foundation for future development of multi-omics-guided diagnostic and therapeutic approaches.",[232,233,234,36],"Acute Respiratory Distress Syndrome (ARDS)","Microbiome Dysbiosis","Multiomics Analysis","2026-01-24",{"date":237,"type":41},"2026-02-02",{"date":239,"type":22},"2026-03-01",{"date":241,"type":22},"2029-12-31",{"name":243,"class":48},"Ruijin Hospital",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":57,"sex":58,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":255,"conditions":256,"keywords":261,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":276},"100612447","epigut-epilepsy-and-gastrointestinal-microbiota-understanding-therapy-response-100612447","NCT07253701","EPIGUT: EPILEPSY AND GASTROINTESTINAL MICROBIOTA: UNDERSTANDING THERAPY RESPONSE","EpiGUT","Inclusion Criteria:\n\n* Patients: Age 2-79 years, newly diagnosed with epilepsy, treatment-naive at time of enrollment\n* Controls: Age 2-79 years\n\nExclusion Criteria:\n\n* Patients: already started ASM treatment (more then one dose), has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy\n* Controls: previous epilepsy diagnosis or ASM treatment, has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy","2 Years","79 Years",{"count":254,"type":22},1500,"The goal of this observational study is to learn how the bacteria in the gut and mouth (called the microbiota) are linked to different types of epilepsy and how they may affect how well seizure medicines work.\n\nResearchers want to answer two main questions:\n\nAre certain types of epilepsy linked to changes in the gut or mouth microbiota? Do the bacteria in the gut change how seizure medicines work for each person?\n\nEpilepsy is a brain condition that causes seizures. Even though there are many medicines for epilepsy, some people still have seizures or side effects. Studies in animals show that gut bacteria can raise or lower the chance of seizures. Smaller studies in people suggest the same thing, but they have been limited in size and scope.\n\nIn this study, researchers will collect biological samples from people who have newly diagnosed epilepsy and from people without epilepsy (called healthy controls). The samples will be tested to learn which bacteria are present. The researchers will then look for patterns that may explain which types of epilepsy are linked to changes in the microbiota.\n\nThe study will also look at whether the bacteria in the gut and mouth affect how well anti-seizure medicines (ASMs) work. For example, the researchers will explore if certain bacteria make medicines work better or worse.\n\nPatients will provide blood, stool and saliva samples. If collected for medical reasons, cerebrospinal fluid (CSF) - the clear liquid that surrounds the brain and spinal cord -will also be used.\n\nHealthy controls will provide stool and saliva samples only\n\nAll participants will be asked to fill an online questionnaire to share health and lifestyle information.\n\nPatients also allow researchers to confidentially access data from medical records related to diagnosis and treatment.\n\nBy comparing data from many participants across Sweden, researchers hope to understand how gut and mouth bacteria influence epilepsy and seizure control.\n\nThis research may help doctors in the future to use a person's microbiota profile to choose the best seizure medicine. The long-term goal is to improve seizure control, reduce side effects, and raise the quality of life for people living with epilepsy.",[257,258,259,36,260],"Epilepsy","Microbiota","Proteomics","Biomarker Discovery",[262,263,264,265,266],"seizures","microbiome","anti-seizure medication","gut-brain-axis","epilepsy","2025-11-19",{"date":269,"type":41},"2025-11-28",{"date":271,"type":41},"2024-02-27",{"date":273,"type":22},"2028-03",{"name":275,"class":48},"Karolinska Institutet",6,{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":289,"conditions":290,"keywords":297,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":49},"100602019","phase-2-effects-of-adjunct-omega-3-long-chain-polyunsaturated-fatty-acids-in-pulmonary-tuberculosis-patient-an-early-bactericidal-activity-and-inflammatory-trial-100602019","NCT07118059","Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial","Effects of Adjunct Omega-3 Long-chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patients: An Early Bactericidal Activity and Inflammatory Activity Trial","TREAT 3","Inclusion Criteria:\n\n* adults aged 18-45 years\n* laboratory confirmed Pulmonary TB defined as a hard copy of a sputum result detected by WHO recommended assay or mycobacteria culture.\n* Women of childbearing potential with a negative pregnancy test on enrollment\n* All participant irrespective of HIV status who consent to have a HIV test during enrollment.\n\nExclusion Criteria:\n\n* Comorbid condition with treatment of NSAIDS is indicated\n* Institutionalized or incarcerated individuals\n* Those on Multiple drug resistance treatment for more than 4 days within the past 6 months or within 1 month to prior to TB treatment initiation\n* Pregnant or breastfeeding women or women who become pregnant in the first 4 weeks of the trial will be withdrawn\n* show lab safety values: AST or ALT \\> x3 upper limit of normal (ULN) or Total bilirubin \\> 2x the ULN, Neutrophils ≤ 700\u002Fmm³, Platelets \\\u003C 50,000\u002Fmm³, Haemoglobin \\\u003C 8 g\u002FdL, Serum creatinine \\> 2× ULN.\n* Are receiving or planning treatment with any of the following in the 3 months before or during the trial:\n\nAnticoagulants Immune-modulating therapy (e.g., cancer treatment, oral\u002Finhaled corticosteroids) Antacids or proton pump inhibitors (PPIs)\n\n* Have a known allergy or sensitivity to fish or fish oil.\n* Have a recent history (within 2 years) or current clinical evidence of:\n\nPeptic ulcer disease or GI bleeding Coagulopathy or bleeding disorders Kidney or liver disease requiring hospitalisation Cardiovascular disease or significant risk factors for it\n\n-Are HIV-positive and meet any of the following: CD4 count \\\u003C 100 cells\u002Fmm³ Viral load \\> 400 copies\u002FmL (if on ART) Not yet on ART but are expected to initiate treatment during the 8-week intervention phase\n\n* Report high-risk alcohol use (average \\>4 units\u002Fday or binge drinking patterns)\n* Have any other medical condition or situation that, in the investigator's opinion, may interfere with protocol adherence or data interpretation.\n* Plan to relocate from the study area within the next 3 months.\n* Are currently using omega-3 or omega-6 supplements and are unwilling to stop for the duration of the study.","45 Years",{"count":287,"type":22},40,[25],"The goal of this randomized controlled trial is to evaluate the early bactericidal activity, early inflammatory response, and safety of omega-3 long chain polyunsaturated fatty acid (n-3 PUFA) supplementation in adult patients (aged 18- 45 years) with newly diagnosed, bacteriologically confirmed drug-sensitive pulmonary tuberculosis.\n\nThe main questions it aims to answers are:\n\n* Does adjunct n-3 LCPUFA supplementation reduce the sputum culture time to positivity\n* Does it improve inflammatory markers and TB treatment outcomes compared to placebo Researchers will compare daily supplementation with \\~2g n-3 LCPUFA (EPA and DHA ) to placebo (high linoleic sunflower oil) to determine effects on bactericidal activity, inflammation, and clinical outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either n-3 LCPUFA or Placebo daily for 8 weeks with the intensive phase of TB treatment\n* Attend clinical visit baseline, and follow up visit mostly weekly for 2 months and then monthly for 4 months of the continuous phase of TB treatment\n* Provide blood, sputum and urine samples for biomarkers and metabolomic analysis\n* Undergo assessments of iron status, body composition and muscle strength",[291,292,293,294,36,295,296],"Tuberculosis","Inflammation Biomarkers","Liver Function Tests","Iron Status","Nutritional Status","Clinical Outcomes",[298,299,300,301,302],"Pulmonary tuberculosis","Patients","adjunct omega-3 long chain polyunsaturated fatty acid","early bactericidal","safety trial","2025-08-04",{"date":305,"type":41},"2025-08-12",{"date":307,"type":22},"2025-08",{"date":309,"type":22},"2026-12",{"name":311,"class":48},"North-West University, South Africa",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":333,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":49},"100585948","phase-3-semaglutide-treatment-in-type-1-diabetes-100585948","NCT06909006","Semaglutide Treatment in Type 1 Diabetes","Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial","OBES1TY","Inclusion Criteria:\n\n* Type 1 Diabetes for more than 3 years\n* BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis\n\nExclusion Criteria:\n\n* Treated with GLP1-RAs within last 6 months\n* Known intolerance for semaglutide\n* Other forms of diabetes\n* Pregnant or nursing women\n* Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives\n* Liver disease with elevated plasma alanine aminotransferase (ALT) \\> five times and plasma aspartate aminotransferase (AST) \\> five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)\n* Acute or chronic pancreatitis\n* Cancer, unless in complete remission for \\> 5 years or unless basocellular carcinomas\n* History of thyroid adenoma or carcinoma\n* Alcohol\u002Fdrug abuse\n* Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation\n* Receipt of an investigational drug within 30 days prior to visit 0 \u002F Simultaneous participation in any other clinical intervention trial",{"count":321,"type":22},122,[26],"The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.",[325,326,327,328,329,330,36,331,332],"Obesity in Diabetes","Obesity\u002FTherapy","Type 1 Diabetes Mellitus (T1DM)","Insulin Sensitivity\u002FResistance","Semaglutide","Lipidomics","Weight Loss","Glycemic Control for Diabetes Mellitus",[329,203,334,335,336,337,338,339,340,341],"Type 1 Diabetes","Obese Type 1 Diabetics","Insulin sensitivity","Insulin resistance","Weight loss","GLP1-RA","GLP1","Wegovy",{"date":343,"type":41},"2025-08-08",{"date":345,"type":22},"2025-10",{"date":347,"type":22},"2028-06",{"name":349,"class":48},"Nordsjaellands Hospital",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":123,"enrollmentInfo":357,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":359,"conditions":360,"keywords":365,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":49},"100426368","bio-significance-of-lpc160-in-fibromyalgia-100426368","NCT04832100","Bio-significance of LPC16:0 in Fibromyalgia","A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia","Inclusion Criteria:\n\n1\\. Clinical diagnosis of fibromyalgia\n\nExclusion Criteria:\n\n1. Systemic rheumatological or immune disorders (e.g., systemic lupus erythematosus, inflammatory myositis),\n2. Systemic use of corticosteroids,\n3. Pregnancy,\n4. Chronic diseases under poor control\n5. Malignancies.",{"count":358,"type":22},245,"Fibromyalgia (FM) is a very common but mysterious pain disorder characterized by chronic widespread muscular pain. Fatigue, anxiety and depression are common comorbidities. The syndrome is commonly associated with several symptoms, including fatigue, sleeping disturbance, cognitive impairment, and comorbid pain syndrome, especially irritable bowel symptoms and temporomandibular disease. Anxiety and depression are common psychiatric co-morbidies. Daily stress is believed to trigger or aggravate pain conditions. These symptoms can markedly affect patients' quality of life, and even lead to disability. So far, the etiology and pathogenesis are largely unknown, and diagnostic biomarkers and curative treatment remain to be developed. Recent technological advances enable scientists to explore mechanisms by genetic, transcriptomic, proteomic, and metabolomic researches. However, no definitive result has been concluded for clinical practice so far.\n\nIn this study, the investigators use tailored questionnaires to evaluate fibromyalgia and associated symptoms, including numeric rating scale for soreness, widespread soreness index, Fibromyalgia impact questionnaire, Hospital Anxiety and Depression Scale, and perceived stress scale. The investigators also use metabolomics and lipidomic approach to probe the potential pathophysiology of fibromyalgia. In our prior translation research (PMID: 32907805), the investigators found that excessive LPC16:0 resulting from lipid oxidization inflicts psychological stress-induced chronic non-inflammatory pain via activating ASIC3. In this content, our prior translational research identified a potential nociceptive ligand that causes fibromyalgia symptoms, which is likely to function as biomarkers for diagnosis or disease monitor. In the current clinical investigation, the investigators aim to reversely translate the novel findings in animal studies and validate the bio-significance of LPC16:0 for fibromyalgia with clinical approaches.",[361,362,363,364,36,330],"Fibromyalgia, Primary","Pain","Soreness, Muscle","Oxidative Stress",[366,367,368,369,134],"lysophosphotidylcholine","fibromyalgia","pain","soreness","2025-06-22",{"date":372,"type":41},"2025-06-26",{"date":374,"type":41},"2021-06-01",{"date":376,"type":22},"2027-06-30",{"name":378,"class":48},"Kaohsiung Medical University Chung-Ho Memorial Hospital",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":390,"conditions":391,"keywords":395,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":404,"locationsCount":49},"100507784","early-phase-1-supplemental-oxygen-in-pulmonary-embolism-so-pe-100507784","NCT05891886","Supplemental Oxygen in Pulmonary Embolism (SO-PE)","SO-PE","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Confirmed Pulmonary Embolism (PE) on imaging \\\u003C24 hours prior to enrollment\n* New symptom onset and \u002F or worsening symptoms \\\u003C72 hours\n* Confirmation of right ventricular dysfunction (RVD) by clinician\n* Oxygen saturation ≥90% while breathing room air\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Use of vasopressors or mechanical circulatory support\n* Planned use of thrombolytics or plan for embolectomy\n* Oxygen saturation \\\u003C90% while breathing room air\n* New onset arrhythmia\n* History of pulmonary hypertension, severe chronic obstructive pulmonary disease (COPD) requiring home oxygen or chronic steroid use, hypoventilation syndrome requiring continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP), or congestive heart failure (CHF) with LV ejection fraction \\\u003C 40% or chronic oxygen therapy\n* Known pregnancy\n* Vasodilator medication used in the past 24 hours\n* Symptom onset ≥72 hours\n* Inability to wear a face mask\n* Inability to obtain adequate baseline echocardiogram",{"count":387,"type":22},80,[389],"EARLY_PHASE1","A study of how supplemental oxygen helps patients with acute pulmonary embolism (PE).\n\nHypothesis: Oxygen affects right ventricular dysfunction (RVD) in patients with acute pulmonary embolism (PE) primarily by relieving hypoxic pulmonary vasoconstriction and reducing pulmonary pressure (PA) pressure, and that this process is metabolically driven.",[392,393,36,394],"Pulmonary Embolism","Venous Thromboembolism","Oxygen Inhalation Therapy",[392,396,397],"PE","Right ventricular dysfunction","2025-06-12",{"date":400,"type":41},"2025-06-15",{"date":402,"type":41},"2023-10-01",{"date":376,"type":22},{"name":405,"class":48},"Massachusetts General Hospital",{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":427,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":436,"locationsCount":49},"100589205","the-impact-of-daily-intake-of-short-chain-fatty-acids-on-cardiometabolic-risk-factors-in-individuals-at-risk-for-metabolic-syndrome-100589205","NCT06951386","The Impact of Daily Intake of Short-chain Fatty Acids on Cardiometabolic Risk Factors in Individuals at Risk for Metabolic Syndrome","The Impact of 12 Weeks Intervention With Plant-based Oat Drink Rich in Short-chain Fatty Acids on Postprandial Lipidemia in Individuals at Risk for Metabolic Syndrome","12OATS","Inclusion Criteria:\n\n* male and female participants\n* central obesity ( BMI ≥ 25 kg\u002Fm² or waist circumference ≥ 80 cm for women\u002F ≥ 94 cm for men)\n* One additional risk factor for metabolic syndrome:\n\n  1. Insulin resistance (HOMA-IR ≥ 1.7 or fasting glucose ≥ 100 mg\u002Fdl)\n  2. Triglyceride concentration ≥ 150 mg\u002Fdl\n  3. HDL-cholesterol \\\u003C 40 mg\u002Fdl for women\u002F \\\u003C 50 mg\u002Fdl for men\n  4. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg\n* knowledge of English\n\nExclusion Criteria:\n\n* gastrointestinal disorders such as IBD, IBS, celiac disease, chronic constipation, chronic diarrhoea\n* history of abdominal surgery, except for appendectomy\n* Use of antihypertensive, cholesterol lowering, glucose-regulating drugs and corticosteroids\n* Use of antibiotics 3 months prior to the start or during the study\n* Use of probiotics and prebiotics 2 weeks prior to the start of the study\u002F during the study\n* Being on weight loss, gluten-free, lactose-free or vegan diet\n* Pregnancy, lactation or wish to become pregnant\n* Previous or current substance\u002F alcohol dependence or abuse\n* Hyper- or hypothyroidism\n* Allergy or intolerance to oat milk","65 Years",{"count":416,"type":22},50,[63],"During this study, the effect of short-chain fatty acids on blood lipaedemia, glycemia, anthropometrics, blood pressure and energy expenditure will be investigated.",[420,421,422,423,424,425,36,426],"Energy Expenditure","Metabolic Syndrome","Anthropometry","Body Composition","Glycemia","Lipaemia","Blood Pressure",[428,429],"short-chain fatty acids","cardiometabolic health","2025-04-30",{"date":432,"type":41},"2025-05-04",{"date":434,"type":41},"2025-02-11",{"date":105,"type":22},{"name":437,"class":48},"KU Leuven",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":445,"enrollmentInfo":446,"targetDuration":448,"studyType":92,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":49},"100580930","establishing-a-longitudinal-cohort-study-of-lung-cancer-using-tissue-and-peripheral-blood-metabolomics-100580930","NCT06843707","Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.","Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.","Inclusion Criteria:\n\n1. Signing of the informed consent form;\n2. Male or female, aged 18-75 years;\n3. Patients with lung nodules confirmed by CT examination;\n4. Good preoperative pulmonary function cooperation and complete reporting;\n5. Preoperative chest single\u002Fdual phase CT scans without significant artefacts and with complete imaging;\n6. The interval between preoperative pulmonary function and single\u002Fdual phase CT scans does not exceed one month.\n\nExclusion Criteria:\n\n1. Poor preoperative pulmonary function cooperation or missing reports;\n2. Preoperative chest single\u002Fdual phase CT scans exhibit significant artefacts or image omission;\n3. The interval between preoperative pulmonary function and single\u002Fdual phase CT scans exceeds one month;\n4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);\n5. Coexisting with other severe functional impairments;\n6. Patients with obstructive lesions such as airway or esophageal stenosis;\n\n(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.","75 Years",{"count":447,"type":22},2500,"5 Years","This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.",[451,452,453,36],"Lung Cancer","Lung","Lung Cancer (NSCLC)","2025-02-24",{"date":456,"type":41},"2025-02-25",{"date":458,"type":41},"2024-01-01",{"date":460,"type":22},"2027-12-31",{"name":462,"class":48},"The First Affiliated Hospital of Guangzhou Medical University",{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":57,"sex":58,"minAge":470,"maxAge":59,"enrollmentInfo":471,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":480,"leadSponsor":481,"locationsCount":49},"100521736","metabolic-mechanisms-of-the-electrophysiological-biomarkers-for-response-to-methylphenidate-treatment-in-children-with-adhd-100521736","NCT06073470","Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD","Exploration of the Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With Attention-Deficit\u002FHyperactivity Disorder","1. Patients with ADHD\n\n   1. Inclusion Criteria\n\n      * Patients, aged 6 to 18 years, meet the DSM-5 diagnostic criteria for ADHD.\n      * At baseline, patients have a Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) score greater than 4.\n      * Patients have a Full IQ (FIQ) score greater than 80.\n   2. Exclusion Criteria\n\n      * Patients have a major psychiatric disorder, such as autism spectrum disorder, schizophrenia, affective disorders, or substance use disorders.\n      * Patients have a major disorder of central nervous system, such as epilepsy.\n      * Patients have a major systemic disease, such as diabetes mellitus or cardiovascular diseases.\n      * Patients have ever received any medication to treat the clinical symptoms of ADHD.\n2. Neurotypical participants:\n\n   1. Inclusion Criteria\n\n      * aged 6 to 18 years\n      * All of the neurotypical participants have no psychiatric disorder in lifetime according to the diagnostic criteria of DSM-5.\n   2. Exclusion Criteria\n\n      * participants have any disorder of central nervous system or major systemic disease\n      * participants have ever taken any psychotropic drug, or who have FIQ scores less than 80, will be excluded from the present study.","6 Years",{"count":472,"type":22},160,"To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.",[475,36],"Methylphenidate","2024-03-25",{"date":478,"type":41},"2024-03-26",{"date":458,"type":41},{"date":460,"type":22},{"name":482,"class":48},"National Taiwan University Hospital",{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":491,"enrollmentInfo":492,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":502,"leadSponsor":504,"locationsCount":4},"100517745","involvement-of-the-gut-microbiota-in-calcified-aortic-stenosis-100517745","NCT06021535","Involvement of the Gut Microbiota in Calcified Aortic Stenosis","Involvement of the Gut Microbiota and Its Metabolites in the Pathophysiology of Calcified Aortic Stenosis","Gut-CAS","Inclusion Criteria:\n\n* Group of patients with CAS:\n* Calcified aortic stenosis diagnosed on a cardiac ultrasound or CT not older than 3 months\n* Severe aortic stenosis: surgical indication based on symptoms and ultrasound data (high gradient aortic stenosis : Vmax\\> 4m\u002Fs, mean gradient \\> 40mmHg, area \\\u003C 1cm², low flow low-gradient CAS: left ventricular ejection fraction (LVEF) \\\u003C 40%, Vmax\\\u003C 4m\u002Fs, mean gradient \\\u003C 40mmHg, area \\\u003C 1cm², paradoxical low-gradient CAS: LVEF \\> 55%, Vmax\\\u003C 4m\u002Fs, mean gradient \\\u003C 40mmHg, area \\\u003C 1cm²)\n* Moderate CAS: 3m\u002Fs \\\u003CVmax\\\u003C 4m\u002Fs, 20mmHg \\\u003C mean gradient \\\u003C 40mmHg\n* Mild CAS: 2,6m\u002Fs \\\u003C Vmax \\\u003C 2.9m\u002Fs, mean gradient \\\u003C 20mmHg\n* Aortic sclerosis: calcified remodeling of the aortic valve visible on ultrasound or CT.\n\nControl group - free of CAS:\n\n\\- No calcified aortic stenosis verified on a cardiac ultrasound or CT not older than 3 months\n\nExclusion Criteria:\n\n* Treatment interfering with the composition of the intestinal microbiota: local or systemic corticosteroids within the last 3 months, antibiotics within the last 3 months, antiretrovirals, bile acid chelators (questran and colesevelam), HIV-targeted antiretroviral therapies, selective serotonin reuptake inhibitor-type antidepressants\n* Clinical criteria: history of cholecystectomy, documented chronic liver disease in the patient, failure to fast on the day of the blood test, inflammatory bowel disease\n* Patients requiring emergency intervention (myocardial infarction, acute aortic or mitral insufficiency, cardiogenic shock).\n* AS of rheumatic origin, infective endocarditis.","90 Years",{"count":493,"type":22},100,"Calcific aortic stenosis (CAS) is a disease characterized by progressive calcification of the aortic valve, obstructing the passage of blood from the left ventricle into the general circulation. It is the most frequent cause of valve disease in the elderly. To date, no means of preventing the disease has been discovered, and the only treatment available is valve replacement during cardiac surgery, or percutaneous implantation of a valve prosthesis when the narrowing becomes severe and causes symptoms.\n\nThe intestinal flora or microbiota, the reservoir of all the microorganisms in the gut, is implicated in numerous diseases, particularly of the intestine. But to date, no study has established a link between CAS and microbiota. The intestinal microbiota acts through molecules produced by itself or the host and passing into the bloodstream. In the pathophysiology of CAS, the valve leaflets are breached and do not heal. These molecules can enter and have beneficial or deleterious effects, in particular promoting calcification of aortic valve cells.\n\nConcrete objectives:\n\nImprove understanding of calcific aortic stenosis in humans Study the composition of intestinal flora in patients with aortic stenosis and compare it with healthy subjects Study the molecules in the intestinal flora likely to be involved in the development of aortic stenosis in humans.",[496,497,36],"Aortic Stenosis","Gastrointestinal Microbiome","2023-08-29",{"date":500,"type":41},"2023-09-01",{"date":458,"type":22},{"date":503,"type":22},"2028-12-31",{"name":505,"class":48},"Insel Gruppe AG, University Hospital Bern",{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":514,"conditions":515,"keywords":522,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":528,"leadSponsor":530,"locationsCount":49},"100503374","omic-technologies-applied-to-the-study-of-b-cell-lymphoma-for-the-discovery-of-diagnostic-and-prognosis-biomarkers-100503374","NCT05834426","Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers","Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers","Inclusion Criteria:\n\n* 18 years and older;\n* Both sexes;\n* Patients with confirmed histopathological diagnosis of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma;\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2;\n* Patient intending to receive full-dose treatment (Monoclonal antibodies plus anthracycline based combination chemotherapy);\n* Staged with PET-CT or CT.\n\nExclusion Criteria:\n\n* Patients with comorbidities that may interfere with the interpretation of the results (CKD in dialysis phase, Autoimmune diseases, uncontrolled Diabetes Mellitus (DM), symptomatic Heart Failure (CHF), HIV positive, positive serology for hepatitis B and C);\n* Patients requiring multiple blood transfusions (4 or more blood components for the same period or cause);\n* Pregnant women;\n* First-line treatment in another institution;\n* Diffuse transformed Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",{"count":416,"type":22},"The goal of this observational study is to determine the plasma metabolomic profile in diffuse large B-cell lymphoma and high-grade B lymphomas patients before, during and after treatment by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)",[516,517,518,519,520,521,36],"Lymphoma, B-Cell","Neoplasms","Cancer","High-grade B-cell Lymphoma","Diffuse Large B Cell Lymphoma","Non Hodgkin Lymphoma",[523],"Metabolomic Analysis","2023-06-19",{"date":526,"type":41},"2023-06-22",{"date":500,"type":22},{"date":529,"type":22},"2026-08-31",{"name":531,"class":48},"Sociedad de Lucha Contra el Cáncer del Ecuador"]